A correction occurred in the article by Sokolow AG et al, titled “Safety of Live Attenuated Influenza Vaccine in Children With Asthma” published in the April 2022 issue of Pediatrics (2022;149(4):e2021055432; doi:10.1542/peds.2021-055432).

On page 2, under Methods, paragraph 2, this read: “After informed consent and assent were obtained, participants were randomly assigned 1:1 to receive either a single intranasal dose of LAIV4 or an intramuscular injection of IIV4.” This should have read: “After informed consent and assent were obtained, participants were randomly assigned 1:1 to receive either a single intranasal dose of LAIV4 (FluMist® Quadrivalent, AstraZeneca) or an intramuscular injection of IIV4 (Fluzone® Quadrivalent Vaccine, Sanofi Pasteur).”

The authors state that the purpose of this correction is to provide the types of vaccines used in the study. While LAIV4 has only one manufacturer, IIV4 is ambiguous; therefore, they have sought to clarify in the text.

The online article has been...

You do not currently have access to this content.